A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.
Atrasentan has been studied across 19 research domains including 🫘 Kidney, 🔬 Oncology, 🔥 Metabolic, ❤️ Cardiovascular, 🔬 Inflammation. The primary research focus is 🫘 Kidney with 33% of studies addressing this area.
The following compounds share molecular targets with Atrasentan, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Atrasentan is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.